In addition to RB-164™, Radiance is developing RB-201™, a HER2/TROP2 Bispecific ADC which is currently in preclinical stages. For more information on Radiance visit www.radiancebiopharma.com.

HUNTSVILLE, Ala., Jan. 6, 2022 /PRNewswire/ -- Radiance Technologies, Inc. (Radiance) is pleased to announce the promotion of Mr. Tim Tinsley to the office of President.